Tisch Cancer Institute at Mount Sinai


 

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Ruxolitinib for JAK Inhibitor–Naïve Patients With MF

125 views
December 27, 2024
Comments 0
Login to view comments. Click here to Login